CP Holdings

CP Pharmaceutical Group, often operating through its primary listed entity Sino Biopharmaceutical Limited, is a leading research-driven pharmaceutical conglomerate in China. The company maintains a dominant market position in therapeutic areas such as oncology, liver diseases, respiratory infections, and cardiovascular health. Its business model integrates a massive R&D infrastructure with large-scale manufacturing and an extensive commercial distribution network across mainland China. Key subsidiaries include Chia Tai Tianqing (CTTQ) and Beijing Tide Pharmaceutical, which contribute to a robust pipeline of innovative biologics and small molecules. The group is increasingly focused on global expansion through strategic partnerships and the development of next-generation modalities including ADCs and cell therapies.